the internet by establishing LabOnWeb.com, a subscription-based online life sciences research portal. The move put Compugen into competition with other new, similar efforts such as Hyseq’s GeneSolutions.com, eBioinformatics’ BioNavigator, and DoubleTwist.com, the new incarnation of Pangea Systems.
JAMESBURG, NJ--Compugen last month staked out new bioinformatics territory on
Compugen said its site is now in beta at several research institutions including Harvard University, New York University, and Weizmann Institute of Science. The company explained that the platform, which it called a "vital experiment booster and enhancement engine," will integrate web-embedded knowledge into common experimental life science workflow to enhance discovery and increase research productivity. LabOnWeb account pricing was not immediately available.
Martin Gerstel, Compugen’s chairman, remarked, "With biology becoming increasingly computational and the internet assuming a central role in communications, LabOnWeb.com is uniquely positioned to empower life scientists by providing them with new and unprecedented research opportunities over the web." He predicted that the site would facilitate discovery techniques, boost researchers’ productivity, and shorten the healthcare discovery process."
LabOnWeb customers will have access to Compugen’s proprietary data and analysis tools. Compugen said the site will enable "life science researchers to join minds in a global networked community that will significantly contribute to the transformation of the drug discovery process" and that it will "constructively focus individual minds into a problem solving network," allowing members to eliminate redundancies and share knowledge. The site also guarantees confidentiality and security for users.
LanOnWeb’s automated platform presently includes sequence elongation, full-length gene sequences, coding regions, sequence translations, gene functions, gene expression patterns, chromosomal mapping, disease linkage, polymorphism, optimal primers, and sequencing errors. The company said it would post additional data and technologies to the site in coming weeks.